Affordable Access

Publisher Website

Current and potential treatments for primary Sjögren’s syndrome

Authors
Journal
Joint Bone Spine
1297-319X
Publisher
Elsevier
Publication Date
Volume
69
Issue
4
Identifiers
DOI: 10.1016/s1297-319x(02)00411-6
Keywords
  • Primary Sjögren'S Syndrome
  • Tnf-α
Disciplines
  • Medicine

Abstract

Abstract A precise definition of primary Sjögren’s syndrome resting on ˈrevisedˈ or ˈinternationalˈ criteria has been accepted by most experts. This is important because the symptoms of primary Sjögren’s syndrome, namely, dryness, fatigue, and pain, are common in the population at large and can occur in the absence of autoimmune disease as a result of medication use, anxiety and depression, or normal aging. This widely accepted definition is particularly valuable as a tool for obtaining homogenous patient populations for trials of new therapeutic agents. In this review article, before discussing treatments for complications and current hopes about second-line drugs, we present an update on available treatments for the symptomatic triad (dryness, fatigue, and diffuse pain) seen in autoimmune Sjögren’s syndrome and in some cases of isolated sicca syndrome. These very bothersome and permanent symptoms have a negative effect on quality of life. The most recent data show that systemic cholinergic agonists (pilocarpine and cevimiline) are effective in the symptomatic treatment of dryness, that cyclosporine eye drops may relieve ocular symptoms, and that TNFα inhibitors may find a new indication in Sjögren’s syndrome.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

[Current opinion on diagnosis of primary Sjögren's...

on Acta otorhinolaryngologica Ita... August 2002

Current and future challenges in primary Sjögren's...

on Current Pharmaceutical Biotech... August 2012

Primary Sjogren’s Syndrome: Current and Prospectiv...

on Seminars in Arthritis and Rheu... Jan 01, 2008
More articles like this..